Navigation Links
Pfenex Reports Second Quarter 2014 Results and Provides Business Update
Date:8/29/2014

our government contracts, offset in part by a decrease in the protein production service work. 
  • Cost of revenue was $2.5 million in the second quarter of 2014 compared to $1.3 million in the second quarter of 2013.  The increase in cost of revenue was due primarily to the increased development costs for our proprietary novel vaccine programs which are funded by various government agencies.
  • Research and development expenses were $0.9 million for the second quarter of 2014 compared to $1.3 million in the second quarter of 2013.  The decrease in research and development expenses was due in part to an increase in development activity by our partner, Stelis, and resulting decrease in activity by Pfenex, of PF530, as well as manufacturing activity and purchase of comparator material for our product candidate, PF582, phase 1b/2a trial in the year ago period.  We expect research and development expense to increase as we advance our lead candidates and pipeline products.
  • Selling, general and administrative expenses were $2.0 million in the second quarter of 2014 compared to $1.7 million in the second quarter of 2013.  The increase in selling, general and administrative expenses was due to an increase in audit and consulting fees.  We expect selling, general and administrative expenses to increase for activities associated with operating as a public company. 
  • Not including the proceeds from our initial public offering and the exercise of the underwriters' option to purchase additional shares, cash, cash equivalents and short-term investments, excluding restricted cash, was $3.9 million as of June 30, 2014, compared to $5.2 million as of December 31, 2013.  As of June 30, 2014 we had $3.8 million drawn under our $3.9 million revolving credit facility and $4.0 million of restricted cash as collateral for the credit facility.
  • Forward-Looking StatementThis press release contains forward-lo
    '/>"/>

    SOURCE Pfenex Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
    2. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
    3. Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
    4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    9. Pharmasset Reports Fiscal Year End 2011 Financial Results
    10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
    (Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
    (Date:10/20/2014)... , Oct. 20, 2014 PureTech , ... tackling big healthcare problems, announced today the closing ... with participation from Invesco Perpetual, a $120 Billion ... to drive PureTech,s existing pipeline forward and to ... has the scientific creativity to really go for ...
    (Date:10/19/2014)... 20, 2014 OCTOBER 20-22, ... (ABIM). ABIM will take place at ... about ABIM 2014 is now available at ... representing companies and organizations from all over ... information on the latest products and developments ...
    Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
    ... , , , , SEATTLE, ... at the Rodman & Renshaw 11th Annual Healthcare Conference on Wednesday, September 9th at ... Hotel. , , The conference will also be webcast live with ... www.celltherapeutics.com . , , , ...
    ... COLUMBIA, Md., Sept. 2 ACell, Inc. is announcing its participation ... , The conference will be held September 9, ... in New York City. James DeFrancesco, Chief Executive Officer and President, ... at 9:10 AM (EDT) in the Hubbard Room. The presentation is ...
    ... BERLIN, September 2 , - Asset Purchase Agreement ... and NeoBenz(R) Micro, , Intendis GmbH, which ... agreement to acquire two prescription dermatology product lines,from SkinMedica, Inc., a ... Both Desonate(R) and NeoBenz(R) Micro are currently marketed in the ...
    Cached Biology Technology:ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference 2Bayer Acquires Two Prescription Dermatology Product Lines From SkinMedica in the U.S. 2Bayer Acquires Two Prescription Dermatology Product Lines From SkinMedica in the U.S. 3
    (Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
    (Date:10/16/2014)... be cultivated efficiently, they are anything but sustainable: ... monoculture cultivation is becoming increasingly evident. Despite their ... and are regarded as the sole possibility of ... wrongfully, finds Bernhard Schmid, an ecology professor at ... form of agriculture and forestry. After all, a ...
    (Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
    Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
    ... University of Adelaide will rewrite the textbooks on how an ... health and fertility. The study, now published in the journal ... that plays a key role in the development of ovaries and ... women. The discovery is expected to prompt further studies around ...
    ... the scientists visualized seven intermediate forms of the CylR2 ... Their results show that the most instable intermediate form ... findings may contribute to a better understanding of how ... Whether Alzheimer,s, Parkinson,s or Huntington,s Chorea all ...
    ... one of the most aggressive invasive ant species in the ... met its match in the Asian needle ant. Specifically, the ... displacing Argentine ants in an urban environment, indicating that the ... be the next invasive species to see a population boom. ...
    Cached Biology News:Study prompts rethink of how ovaries develop 2Protein 'filmed' while unfolding at atomic resolution 2Protein 'filmed' while unfolding at atomic resolution 3Researchers find Asian needle ants displacing other aggressive invaders 2
    , Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
    ... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Silencer Validated and Silencer ...
    ... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and Silencer Pre-designed siRNAs, ...
    Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
    Biology Products: